Cerebellar Dysfunction in Multiple Sclerosis

Multiple sclerosis (MS) commonly affects the cerebellum causing acute and chronic symptoms. Cerebellar signs contribute significantly to clinical disability, and symptoms such as tremor, ataxia, and dysarthria are particularly difficult to treat. Increasing knowledge concerning the pathophysiology of cerebellar disease in MS from human postmortem studies, experimental models, and clinical trials has raised the hope that cerebellar symptoms will be better treated in the future.

[1]  N. Scolding,et al.  Oxidative injury in multiple sclerosis cerebellar grey matter , 2016, Brain Research.

[2]  M. Hallett Isoniazid and action tremor in multiple sclerosis. , 1985, Journal of neurology, neurosurgery, and psychiatry.

[3]  J. Lechner-Scott,et al.  Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study , 2017, The Lancet Neurology.

[4]  J. De Keyser,et al.  Tremor in multiple sclerosis , 2007, Journal of Neurology.

[5]  M. Deloire,et al.  Cerebellar Assessment in Early Multiple Sclerosis , 2016, The Cerebellum.

[6]  AJ Thompson,et al.  A comprehensive assessment of cerebellar damage in multiple sclerosis using diffusion tractography and volumetric analysis , 2011, Multiple sclerosis.

[7]  S. Aksoy,et al.  Effects of different exercise modalities on ataxia in multiple sclerosis patients: a randomized controlled study , 2017, Disability and rehabilitation.

[8]  J. Zajicek,et al.  Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis ( CAMS study ) : multicentre randomised placebo-controlled trial , 2022 .

[9]  P. Feys,et al.  The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis , 2009, Multiple sclerosis.

[10]  D. Francis,et al.  The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry. , 1986, Journal of neurology, neurosurgery, and psychiatry.

[11]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. , 1991, Brain : a journal of neurology.

[12]  J. Lechner-Scott,et al.  Risk of relapse phenotype recurrence in multiple sclerosis , 2014, Multiple sclerosis.

[13]  Marco Bozzali,et al.  Multiple sclerosis: white and gray matter damage associated with balance deficit detected at static posturography. , 2013, Radiology.

[14]  T. R. K. Varma,et al.  Stereotactic neurosurgery for disabling tremor in multiple sclerosis: thalamotomy or deep brain stimulation? , 2007, British journal of neurosurgery.

[15]  J. Volkmann,et al.  [Deep brain stimulation for tremor in multiple sclerosis : consensus recommendations of the German Deep Brain Stimulation Association]. , 2009, Der Nervenarzt.

[16]  E. Gray,et al.  Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum. , 2012, Brain : a journal of neurology.

[17]  P. Bain,et al.  A study of tremor in multiple sclerosis. , 2001, Brain : a journal of neurology.

[18]  S. Reingold,et al.  The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment , 1999, Multiple sclerosis.

[19]  A. Quattrone,et al.  Lamotrigine therapy for paroxysmal dysarthria caused by multiple sclerosis: a case report , 2011, Journal of Neurology.

[20]  R. Foster,et al.  Reorganization of the axon membrane in demyelinated peripheral nerve fibers: morphological evidence. , 1980, Science.

[21]  Rana Karabudak,et al.  Physiotherapy Approaches in the Treatment of Ataxic Multiple Sclerosis: A Pilot Study , 2001, Neurorehabilitation and neural repair.

[22]  S. Dib-Hajj,et al.  A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis , 2012, Annals of neurology.

[23]  Pierre Grammond,et al.  Contribution of different relapse phenotypes to disability in multiple sclerosis , 2017, Multiple sclerosis.

[24]  M. Benedetti,et al.  A task-oriented circuit training in multiple sclerosis: a feasibility study , 2014, BMC Neurology.

[25]  A. Thompson,et al.  Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. , 1995, Brain : a journal of neurology.

[26]  W. Mcdonald,et al.  The pathophysiology of multiple sclerosis , 2006 .

[27]  J Zajicek,et al.  The effect of cannabis on tremor in patients with multiple sclerosis , 2004, Neurology.

[28]  L. Kappos,et al.  Cerebellar Abnormalities Contribute to Disability Including Cognitive Impairment in Multiple Sclerosis , 2014, PloS one.

[29]  B. Scheithauer,et al.  Inflammatory cortical demyelination in early multiple sclerosis. , 2011, The New England journal of medicine.

[30]  P. Bossuyt,et al.  A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. , 2000, The New England journal of medicine.

[31]  G. Beebe,et al.  Studies on the natural history of multiple sclerosis. V. Long-term survival in young men. , 1970, Archives of neurology.

[32]  D. Wraith,et al.  Fusion between human mesenchymal stem cells and rodent cerebellar Purkinje cells , 2011, Neuropathology and applied neurobiology.

[33]  D. Altmann,et al.  MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction , 2009, Multiple sclerosis.

[34]  Chiara Romualdi,et al.  Magnetic resonance evidence of cerebellar cortical pathology in multiple sclerosis , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[35]  S. Waxman,et al.  Slowly Progressive Axonal Degeneration in a Rat Model of Chronic, Nonimmune-Mediated Demyelination , 2010, Journal of neuropathology and experimental neurology.

[36]  F. Jacques Defining the clinical course of multiple sclerosis: The 2013 revisions , 2015, Neurology.

[37]  S. Waxman Demyelinating diseases--new pathological insights, new therapeutic targets. , 1998, The New England journal of medicine.

[38]  W. Fogel,et al.  Tiefe Hirnstimulation bei Multiple-Sklerose-Tremor , 2009, Der Nervenarzt.

[39]  Hans Lassmann,et al.  Widespread Demyelination in the Cerebellar Cortex in Multiple Sclerosis , 2007, Brain pathology.

[40]  N. Scolding,et al.  Purkinje Cell Pathology and Loss in Multiple Sclerosis Cerebellum , 2014, Brain pathology.

[41]  A. Lo,et al.  Annexin II/p11 is up-regulated in Purkinje cells in EAE and MS , 2003, Neuroreport.

[42]  M. Espir,et al.  Paroxysmal symptoms as the first manifestations of multiple sclerosis. , 1980, Journal of neurology, neurosurgery, and psychiatry.

[43]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. , 1999, Brain : a journal of neurology.

[44]  B. Trapp,et al.  Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions , 2001, Annals of neurology.

[45]  D. Centonze,et al.  GABAergic signaling and connectivity on Purkinje cells are impaired in experimental autoimmune encephalomyelitis , 2012, Neurobiology of Disease.

[46]  M. Hallett,et al.  Treatment of action tremor in multiple sclerosis with isoniazid , 1982, Neurology.

[47]  P. Eldridge,et al.  Tremor reduction and quality of life after deep brain stimulation for multiple sclerosis–associated tremor , 2013, Acta Neurochirurgica.

[48]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[49]  David H. Miller,et al.  Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial , 2010, The Lancet Neurology.

[50]  E. Aronica,et al.  Switch in the expression of mGlu1 and mGlu5 metabotropic glutamate receptors in the cerebellum of mice developing experimental autoimmune encephalomyelitis and in autoptic cerebellar samples from patients with multiple sclerosis , 2008, Neuropharmacology.

[51]  Stefanie Kuerten,et al.  MP4- and MOG:35–55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum , 2007, Journal of Neuroimmunology.

[52]  J. Matsumoto,et al.  Surgical therapy for multiple sclerosis tremor: a 12‐year follow‐up study , 2012, European journal of neurology.

[53]  Vladimir Fonov,et al.  Contribution of the cerebellum to cognitive performance in children and adolescents with multiple sclerosis , 2016, Multiple sclerosis.

[54]  Massimo Filippi,et al.  Cerebellar contribution to motor and cognitive performance in multiple sclerosis: An MRI sub-regional volumetric analysis , 2017, Multiple sclerosis.

[55]  E. Mowry,et al.  The onset location of multiple sclerosis predicts the location of subsequent relapses , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[56]  Marco Molinari,et al.  The cerebellar cognitive profile. , 2011, Brain : a journal of neurology.

[57]  S. Waxman,et al.  Expression of Nav1.8 sodium channels perturbs the firing patterns of cerebellar purkinje cells , 2003, Brain Research.

[58]  M. Filippi,et al.  Relationship between damage to the cerebellar peduncles and clinical disability in multiple sclerosis. , 2014, Radiology.

[59]  R. Swingler,et al.  The morbidity of multiple sclerosis. , 1992, The Quarterly journal of medicine.

[60]  N. Scolding,et al.  Cell fusion in the brain: two cells forward, one cell back , 2014, Acta Neuropathologica.

[61]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[62]  J Newcombe,et al.  Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Y. Blanco,et al.  Midbrain lesions and paroxysmal dysarthria in multiple sclerosis , 2008, Multiple sclerosis.

[64]  P. Duquette,et al.  Isoniazid for tremor in multiple sclerosis , 1985, Neurology.

[65]  A. Coles,et al.  Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients , 2016, Journal of the Neurological Sciences.

[66]  D. Wade,et al.  Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients , 2004, Multiple sclerosis.

[67]  J. Kurtzke Rating neurologic impairment in multiple sclerosis , 1983, Neurology.

[68]  W. Koller Pharmacologic trials in the treatment of cerebellar tremor. , 1984, Archives of neurology.

[69]  Arthur W. Toga,et al.  Purkinje cell loss in experimental autoimmune encephalomyelitis , 2009, NeuroImage.

[70]  A. Pauli,et al.  The effect of core stability training on balance and mobility in ambulant individuals with multiple sclerosis: A multi-centre series of single case studies , 2010, Multiple sclerosis.

[71]  Moses Rodriguez,et al.  Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population , 2004, Movement disorders : official journal of the Movement Disorder Society.

[72]  J. Baskerville,et al.  The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. , 1991, Brain : a journal of neurology.

[73]  B. Weinshenker,et al.  Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis , 2015, Neurology.

[74]  C. Young,et al.  Treatment for ataxia in multiple sclerosis. , 2007, The Cochrane database of systematic reviews.